Thanks for the clarification re NEJM. This could be a nice ancillary indication for Promacta, but I doubt that the incremental revenue will be material for a company of GSK’s size.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”